Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19

Next Previous
X
Search
Trial Profile

A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms MORNINGSKY
  • Sponsors Atea Pharmaceuticals; Roche

    • Most Recent Events

    • 08 May 2023 According to an Atea Pharmaceuticals media release, results from this study were presented at 2023 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023).
    • 12 Apr 2023 Results presented in the Atea Pharmaceuticals Media Release
    • 12 Apr 2023 According to an Atea pharmaceuticals media release, results from this study are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top